BPH AuthorityUnderstand the options. Find the right capability.
18 options · one common schema

Compare the tradeoffs that actually change the decision.

Filter the landscape, choose two to four options, and compare anatomy, recovery, sexual effects, durability, implants, pathology, failure paths, and access side by side.

Evidence reviewed August 14, 2026Clinical review pending; evidence sources are shown

There is deliberately no composite “best” score. Evidence maturity, regulatory status, adoption, access, recovery, and durability are separate dimensions.

Source library
18 of 18 options shown
ConservativeEstablished

Watchful waiting & self-management

Monitor symptoms while using targeted lifestyle changes rather than starting medication or a procedure now.

AnatomyAny prostate size, provided the evaluation has not identified a complication that requires treatment.
RecoveryNo procedural recovery
EjaculationNo direct effect
AccessBroad
Guide
MedicationEstablished

Alpha blockers

Relax smooth muscle around the prostate and bladder outlet to improve flow without shrinking the prostate.

AnatomyCan be used across prostate sizes; size does not determine early symptom response.
RecoveryNo procedural recovery
EjaculationSome agents can reduce or alter ejaculation
AccessBroad
Guide
MedicationEstablished

5-alpha-reductase inhibitors

Gradually shrink enlarged prostate tissue and lower the risk of retention or future surgery in appropriately selected men.

AnatomyMost useful when the prostate is clearly enlarged; commonly discussed above roughly 40 mL or when PSA suggests enlargement.
RecoveryNo procedural recovery
EjaculationMay reduce ejaculate volume or contribute to ejaculatory difficulty
AccessBroad
Guide
MedicationEstablished

Daily tadalafil

A daily PDE5 inhibitor that can improve urinary symptoms and erectile function, without shrinking the prostate.

AnatomyNot limited to one prostate size
RecoveryNo procedural recovery
EjaculationUsually preserves ejaculation
AccessBroad
Guide
MedicationEstablished for storage symptoms

Bladder-directed medications

Antimuscarinic or beta-3 agonist medication may help urgency and frequency when the bladder—not only the prostate—is driving symptoms.

AnatomySelection depends more on symptom pattern and residual urine than prostate size
RecoveryNo procedural recovery
EjaculationUsually neutral
AccessBroad
Guide
MedicationEstablished

Combination medication

Pairs medications with different roles—for example fast symptom relief plus long-term progression reduction.

AnatomyThe exact combination depends on prostate size, progression risk, residual urine, erectile priorities, and symptom pattern.
RecoveryNo procedural recovery
EjaculationSide effects can accumulate across medications
AccessBroad
Guide
Tissue-removing / incisional procedureEstablished

Transurethral incision of the prostate

Makes one or more internal incisions at the bladder outlet rather than removing a large amount of tissue.

AnatomyPrimarily a small-gland option, commonly 30 mL/g or less
RecoverySeveral days of urinary irritation; activity restrictions vary
EjaculationLower risk of dry/retrograde ejaculation than TURP, but not zero
AccessBroad but selectively used
Guide
Office / minimally invasiveEstablished with anatomy limits

Prostatic urethral lift

Permanent implants pull obstructing prostate tissue away from the urethra without cutting or heating it.

AnatomyStrongest comparative evidence is in moderate-size glands. FDA labeling permits men 45+ and includes lateral or median-lobe hyperplasia, with prostate volume over 100 cc listed as a contraindication.
RecoveryUrinary burning, urgency, pelvic discomfort, or blood in urine are common early
EjaculationUsually preserved
AccessBroad
Guide
Office / minimally invasiveEstablished with expanding size evidence

Water-vapor thermal therapy

Injects controlled water vapor into selected prostate tissue, which shrinks over the following weeks and months.

AnatomyFDA labeling covers men 50+ with prostate volume 30–150 cm³ and permits central-zone and median-lobe treatment. Evidence is deepest in smaller/moderate glands, with newer prospective data in 80–150 cm³ glands.
RecoveryEarly urgency, frequency, burning, blood, pelvic discomfort, and temporary symptom worsening are common
EjaculationUsually preserved, not guaranteed
AccessBroad
Guide
Office / minimally invasiveNewer

Temporary implanted nitinol device

A temporary nitinol device stays in the prostatic urethra for roughly five to seven days, then is removed.

AnatomyFDA indication is for men 50+; pivotal studies used selected moderate-size anatomy, so prostate length, size, and middle-lobe configuration require confirmation.
RecoveryTemporary pelvic pressure, urgency, blood, discomfort, or urinary symptoms while the device is in place
EjaculationGenerally preserved in trials
AccessLimited to moderate
Guide
Office / minimally invasiveNewer

Drug-coated balloon dilation

Dilates the prostatic urethra and transfers paclitaxel locally to help maintain the opening.

AnatomyFDA indication is for obstructive BPH symptoms in men 50+; trial-based anatomy and urethral dimensions still matter.
RecoveryUrinary burning, blood, urgency, frequency, or temporary retention can occur
EjaculationDesigned to preserve sexual function; individual outcomes vary
AccessLimited
Guide
New implant technologyRecently FDA approved

New permanent or removable implants

Two implant platforms received FDA approval in late 2025, creating new office-oriented options with early but still maturing follow-up.

AnatomyZenflow labeling: prostate 25–80 cc and prostatic urethral length 25–45 mm. ProVee labeling: prostate 30–80 cc and prostatic urethral length at least 3.75 cm.
RecoveryLikely urinary irritation, blood, urgency, or retention risk typical of prostatic implants; use current device labeling
EjaculationPreservation is a design goal; long-term real-world estimates remain limited
AccessEarly rollout
Guide
Operating-room tissue removalEstablished newer surgery

Robotic waterjet ablation

Uses ultrasound-guided robotic planning and a high-velocity saline jet to remove a mapped portion of obstructing prostate tissue.

AnatomyFDA labeling does not state a prostate-size limit. Prospective evidence is strongest from 30–150 mL, including middle-lobe anatomy.
RecoveryBlood in urine, urgency, burning, fatigue, and temporary restrictions are expected; bleeding management matters
EjaculationPreserved more often than after standard TURP in trials, but dry or reduced ejaculation still occurs
AccessGrowing
Guide
Interventional radiologyEstablished but selection-dependent

Prostate artery embolization

Blocks selected prostate arteries through a wrist or groin catheter so the gland gradually shrinks.

AnatomyOften considered for larger glands or patients prioritizing a nontransurethral approach; arterial anatomy, atherosclerosis, and bladder function matter.
RecoveryPelvic discomfort, urinary symptoms, fatigue, and post-embolization symptoms may occur for days
EjaculationUsually preserved
AccessModerate
Guide
Operating-room tissue removalReference standard

Transurethral resection of the prostate

Endoscopically removes obstructing prostate chips to create a wider urinary channel.

AnatomyA classic option for moderate-size glands, commonly 30–80 mL; larger glands may be treated depending on technique and expertise.
RecoveryBleeding, urgency, frequency, burning, fatigue, and temporary activity restrictions are expected
EjaculationDry/retrograde ejaculation is common
AccessBroad
Guide
Operating-room tissue vaporizationEstablished

Photoselective vaporization

A laser vaporizes obstructing tissue while providing strong hemostasis.

AnatomyCommonly used for small-to-moderate glands and selected larger glands, depending on platform and surgeon experience.
RecoveryUrinary burning, frequency, urgency, blood, and temporary activity restrictions are common
EjaculationDry/retrograde ejaculation is common
AccessBroad
Guide
Operating-room enucleationEstablished, size-independent

Laser enucleation of the prostate

Separates and removes the obstructing adenoma along the prostate capsule, making it effective across a very wide size range.

AnatomySize-independent in experienced hands, including very large glands and middle lobes
RecoveryTemporary urgency, burning, blood, fatigue, activity limits, and stress leakage can occur
EjaculationDry/retrograde ejaculation is very common with standard technique
AccessModerate; expertise concentrated
Guide
Major surgeryEstablished

Simple prostatectomy

Removes the enlarged internal adenoma through a robotic, laparoscopic, or open operation while leaving the outer prostate capsule.

AnatomyUsually reserved for substantially enlarged glands, often above 80–100 mL, especially when endoscopic enucleation is unavailable or another bladder operation is needed.
RecoveryHospital stay, catheter, bleeding, fatigue, and several weeks of activity restriction
EjaculationDry/retrograde ejaculation is expected in most standard operations
AccessBroad at referral centers
Guide

Side-by-side treatment comparison

Check the evaluation first